Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies

BACKGROUND: Antitumor therapies targeting HER1/EGFR and HER2, such as monoclonal antibodies (MAbs) and tyrosine-kinase inhibitors (TKIs), have demonstrated a significant clinical benefit, but the emergence of resistance limits long-term efficacy. While secondary HER1 mutations confer tolerance to TK...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergado-Báez, Gretchen, Gonzalez Suarez, Narjara, García, Lisset Chao, Pérez-Martínez, Dayana, Hernández-Fernández, Diana Rosa, Fundora-Barrios, Talia, Rodríguez-Álvarez, Antonio, Díaz-Ordaz, Geidy Diana, Lindzen, Moshit, Yarden, Yosef, Sánchez-Ramírez, Belinda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667895/
https://www.ncbi.nlm.nih.gov/pubmed/36408164
http://dx.doi.org/10.3389/fonc.2022.951267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667895/
https://www.ncbi.nlm.nih.gov/pubmed/36408164
http://dx.doi.org/10.3389/fonc.2022.951267

Ejemplares similares